Brevan Howard Capital Management LP Fate Therapeutics Inc Transaction History
Brevan Howard Capital Management LP
- $13.9 Billion
- Q4 2024
A detailed history of Brevan Howard Capital Management LP transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 24,636 shares of FATE stock, worth $26,853. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,636Holding current value
$26,853% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding FATE
# of Institutions
167Shares Held
101MCall Options Held
41.3KPut Options Held
15.9K-
Redmile Group, LLC San Francisco, CA12.9MShares$14 Million1.66% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$11.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$11 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.84MShares$5.28 Million0.16% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.38MShares$4.78 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $106M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...